Cancer Immunotherapy Market

Cancer Immunotherapy Market (Therapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines; Therapeutic Areas - Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood Cancers; End Users - Hospitals, ASC’s (Ambulatory Surgical Centers), and Cancer Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Rep Id : TMRGL4312
  • Published On : Dec 2016
  • No. of Pages : 222
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cancer Immunotherapy Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Therapeutic Area Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends
     4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2016–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
            4.8.1. List of active market participants
                     4.8.1.1.  Manufacturers
                     4.8.1.2.  Distributors
            4.8.2. Forward – Backward Integration Scenario
     4.9. Market Outlook
     4.10. Pipeline Snapshot
     4.11. Cancer Epidemiology
     4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Value Forecast By Therapy Type, 2016–2024
            5.3.1. Monoclonal Antibodies
            5.3.2. Immune Checkpoint Inhibitors
                     5.3.2.1. PD-1/PD-L1
                     5.3.2.2. CTLA-4
            5.3.3. Immune System Modulators
            5.3.4. Cancer Vaccines
            5.3.5. Others
     5.4. Market Attractiveness By Therapy 

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value  Forecast By End User, 2016–2024
            6.3.1. Hospitals
            6.3.2. ASC's
            6.3.3. Cancer Research Institutes
            6.3.4. Clinics
     6.4. Market Attractiveness By End User 

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value  Forecast By Therapeutic Area, 2016–2024
            7.3.1. Lung Cancer
            7.3.2. Colorectal Cancer
            7.3.3. Breast Cancer
            7.3.4. Prostate Cancer
            7.3.5. Melanoma
            7.3.6. Blood Cancers
            7.3.7. Others
     7.4. Market Attractiveness By Therapeutic Area 

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value  Forecast By Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America 
            8.3.5. Middle East and Africa 
     8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
     9.2. Market Value Forecast By Therapy Type, 2016–2024
            9.2.1. Monoclonal Antibodies
            9.2.2. Immune Checkpoint Inhibitors
                     9.2.2.1. PD-1/PD-L1
                     9.2.2.2. CTLA-4
            9.2.3. Immune System Modulators
            9.2.4. Cancer Vaccines
            9.2.5. Others
     9.3. Market Value  Forecast By End User, 2016–2024
            9.3.1. Hospitals
            9.3.2. ASC's
            9.3.3. Cancer Research Institutes
            9.3.4. Clinics
     9.4. Market Value  Forecast By Therapeutic Area, 2016–2024
            9.4.1. Lung Cancer
            9.4.2. Colorectal Cancer
            9.4.3. Breast Cancer
            9.4.4. Prostate Cancer
            9.4.5. Melanoma
            9.4.6. Blood Cancer
            9.4.7. Others
     9.5. Market Value  Forecast By Country, 2016–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Therapy Type
            9.6.2. By End User 
            9.6.3. By Therapeutic Area 
            9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
     10.2.Market Value  Forecast By Therapy Type, 2016–2024
            10.2.1. Monoclonal Antibodies
            10.2.2. Immune Checkpoint Inhibitors
                     10.2.2.1. PD-1/PD-L1
                     10.2.2.2. CTLA-4
            10.2.3. Immune System Modulators
            10.2.4. Cancer Vaccines
            10.2.5. Others
     10.3.Market Value  Forecast By End User, 2016–2024
            10.3.1. Hospitals
            10.3.2. ASC's
            10.3.3. Cancer Research Institutes
            10.3.4. Clinics
     10.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            10.4.1. Lung Cancer
            10.4.2. Colorectal Cancer
            10.4.3. Breast Cancer
            10.4.4. Prostate Cancer
            10.4.5. Melanoma
            10.4.6. Blood Cancer
            10.4.7. Others
     10.5.Market Value  Forecast By Country, 2016–2024
            10.5.1. Germany
            10.5.2. U.K. 
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe
     10.6.Market Attractiveness Analysis 
            10.6.1. By Therapy Type
            10.6.2. By End User 
            10.6.3. By Therapeutic Area 
            10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
     11.2.Market Value  Forecast By Therapy Type, 2016–2024
            11.2.1. Monoclonal Antibodies
            11.2.2. Immune Checkpoint Inhibitors
                     11.2.2.1. PD-1/PD-L1
                     11.2.2.2. CTLA-4
            11.2.3. Immune System Modulators
            11.2.4. Cancer Vaccines
            11.2.5. Others
     11.3.Market Value  Forecast By End User, 2016–2024
            11.3.1. Hospitals
            11.3.2. ASC's
            11.3.3. Cancer Research Institutes
            11.3.4. Clinics
     11.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            11.4.1. Lung Cancer
            11.4.2. Colorectal Cancer
            11.4.3. Breast Cancer
            11.4.4. Prostate Cancer
            11.4.5. Melanoma
            11.4.6. Blood Cancer
            11.4.7. Others
     11.5.Market Value  Forecast By Country, 2016–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. India
            11.5.4. Australia
            11.5.5. New Zealand
            11.5.6. Rest of APAC
     11.6.Market Attractiveness Analysis 
            11.6.1. By Therapy Type
            11.6.2. By End User 
            11.6.3. By Therapeutic Area 
            11.6.4. By Country
12. Latin America Cancer Immunotherapy Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
     12.2.Market Value  Forecast By Therapy Type, 2016–2024
            12.2.1. Monoclonal Antibodies
            12.2.2. Immune Checkpoint Inhibitors
                     12.2.2.1. PD-1/PD-L1
                     12.2.2.2. CTLA-4
            12.2.3. Immune System Modulators
            12.2.4. Cancer Vaccines
            12.2.5. Others
     12.3.Market Value  Forecast By End User, 2016–2024
            12.3.1. Hospitals
            12.3.2. ASC's
            12.3.3. Cancer Research Institutes
            12.3.4. Clinics
     12.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            12.4.1. Lung Cancer
            12.4.2. Colorectal Cancer
            12.4.3. Breast Cancer
            12.4.4. Prostate Cancer
            12.4.5. Melanoma
            12.4.6. Blood Cancer
            12.4.7. Others
     12.5.Market Value  Forecast By Country, 2016–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6.Market Attractiveness Analysis 
            12.6.1. By Therapy Type
            12.6.2. By End User 
            12.6.3. By Therapeutic Area 
            12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
     13.2.Market Value  Forecast By Therapy Type, 2016–2024
            13.2.1. Monoclonal Antibodies
            13.2.2. Immune Checkpoint Inhibitors
                     13.2.2.1. PD-1/PD-L1
                     13.2.2.2. CTLA-4
            13.2.3. Immune System Modulators
            13.2.4. Cancer Vaccines
            13.2.5. Others
     13.3.Market Value  Forecast By End User, 2016–2024
            13.3.1. Hospitals
            13.3.2. ASC's
            13.3.3. Cancer Research Institutes
            13.3.4. Clinics
     13.4.Market Value  Forecast By Therapeutic Area, 2016–2024
            13.4.1. Lung Cancer
            13.4.2. Colorectal Cancer
            13.4.3. Breast Cancer
            13.4.4. Prostate Cancer
            13.4.5. Melanoma
            13.4.6. Blood Cancer
            13.4.7. Others
     13.5.Market Value  Forecast By Country, 2016–2024
            13.5.1. Saudi Arabia
            13.5.2. UAE
            13.5.3. South Africa
            13.5.4. Rest of MEA
     13.6.Market Attractiveness Analysis 
            13.6.1. By Therapy Type
            13.6.2. By End User 
            13.6.3. By Therapeutic Area 
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Amgen, Inc.
                     14.3.1.1. Overview
                     14.3.1.2. Financials
                     14.3.1.3. Recent Developments
                     14.3.1.4. Strategy 
            14.3.2. AstraZenca Plc
                     14.3.2.1. Overview
                     14.3.2.2. Financials
                     14.3.2.3. Recent Developments
                     14.3.2.4. Strategy
            14.3.3. Bristol-Myers Squibb Company
                     14.3.3.1. Overview
                     14.3.3.2. Financials
                     14.3.3.3. Recent Developments
                     14.3.3.4. Strategy
            14.3.4. Eli Lilly and Company
                     14.3.4.1. Overview
                     14.3.4.2. Financials
                     14.3.4.3. Recent Developments
                     14.3.4.4. Strategy
            14.3.5. F.Hoffmann-La Roche Ltd.
                     14.3.5.1. Overview
                     14.3.5.2. Financials
                     14.3.5.3. Recent Developments
                     14.3.5.4. Strategy
            14.3.6. GlaxoSmithKline Plc.
                     14.3.6.1. Overview
                     14.3.6.2. Financials
                     14.3.6.3. Recent Developments
                     14.3.6.4. Strategy
            14.3.7. Janssen Biotech, Inc.
                     14.3.7.1. Overview
                     14.3.7.2. Financials
                     14.3.7.3. Recent Developments
                     14.3.7.4. Strategy
            14.3.8. Merck & Co.
                     14.3.8.1. Overview
                     14.3.8.2. Financials
                     14.3.8.3. Recent Developments
                     14.3.8.4. Strategy
            14.3.9. Novartis AG
                     14.3.9.1. Overview
                     14.3.9.2. Financials
                     14.3.9.3. Recent Developments
                     14.3.9.4. Strategy
            14.3.10. Pfizer, Inc.
                     14.3.10.1. Overview
                     14.3.10.2. Financials
                     14.3.10.3. Recent Developments
                     14.3.10.4. Strategy
            14.3.11. Sanofi
                     14.3.11.1. Overview
                     14.3.11.2. Financials
                     14.3.11.3. Recent Developments
                     14.3.11.4. Strategy
            14.3.12. Spectrum Pharmaceuticals, Inc.
                     14.3.12.1. Overview
                     14.3.12.2. Financials
                     14.3.12.3. Recent Developments
                     14.3.12.4. Strategy
            14.3.13. Takeda Pharmaceuticals
                     14.3.13.1. Overview
                     14.3.13.2. Financials
                     14.3.13.3. Recent Developments
                     14.3.13.4. Strategy

List of Tables

Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2016–2024
Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2016–2024
Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2016–2024
Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2016–2024
Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2016–2024

List of Figures

Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2015–2024
Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2016–2024
Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2016–2024 
Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2016–2024
Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2016–2024 
Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2016–2024
Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type
Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2016–2024
Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2016–2024 
Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)
Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area
Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2016–2024
Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2016–2024 
Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2016–2024
Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2016–2024
Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2016–2024
Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2016–2024 
Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2016–2024
Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2016–2024
Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC’s, 2016–2024
Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2016–2024
Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2016–2024 
Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User
Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2016 and 2024
Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region
Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country
Figure 31: North America Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 33: North America Market Value Share Analysis, by End-User, 2016 and 2024
Figure 34: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User
Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area 
Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User
Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country
Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User
Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2016 and 2024
Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User
Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country
Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2016 and 2024
Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2016 and 2024
Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2016 and 2024
Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2016–2024
Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type
Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area
Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User